Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/6556
| Title: | The effects of β-glucan on human immune and cancer cells | Authors: | Chan, GCF Chan, WK Sze, MYD |
Issue Date: | 10-Jun-2009 | Source: | Journal of hematology & oncology, 10 June 2009, v, 2, 25, p. 1-11 | Abstract: | Non-prescriptional use of medicinal herbs among cancer patients is common around the world. The alleged anti-cancer effects of most herbal extracts are mainly based on studies derived from in vitro or in vivo animal experiments. The current information suggests that these herbal extracts exert their biological effect either through cytotoxic or immunomodulatory mechanisms. One of the active compounds responsible for the immune effects of herbal products is in the form of complex polysaccharides known as β-glucans. β-glucans are ubiquitously found in both bacterial or fungal cell walls and have been implicated in the initiation of anti-microbial immune response. Based on in vitro studies, β-glucans act on several immune receptors including Dectin-1, complement receptor (CR3) and TLR-2/6 and trigger a group of immune cells including macrophages, neutrophils, monocytes, natural killer cells and dendritic cells. As a consequence, both innate and adaptive response can be modulated by β-glucans and they can also enhance opsonic and non-opsonic phagocytosis. In animal studies, after oral administration, the specific backbone 1→3 linear β-glycosidic chain of β-glucans cannot be digested. Most β-glucans enter the proximal small intestine and some are captured by the macrophages. They are internalized and fragmented within the cells, then transported by the macrophages to the marrow and endothelial reticular system. The small β-glucans fragments are eventually released by the macrophages and taken up by other immune cells leading to various immune responses. However, β-glucans of different sizes and branching patterns may have significantly variable immune potency. Careful selection of appropriate β-glucans is essential if we wish to investigate the effects of β-glucans clinically. So far, no good quality clinical trial data is available on assessing the effectiveness of purified β-glucans among cancer patients. Future effort should direct at performing well-designed clinical trials to verify the actual clinical efficacy of β-glucans or β-glucans containing compounds. | Keywords: | Cell proliferation Cell survival Immune system Immunologic factors |
Publisher: | BioMed Central Ltd. | Journal: | Journal of hematology & oncology | ISSN: | 1756-8722 | DOI: | 10.1186/1756-8722-2-25 | Rights: | © 2009 Chan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Appears in Collections: | Journal/Magazine Article |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Chan_Human_Immune_Cancer.pdf | 1.33 MB | Adobe PDF | View/Open |
Access
View full-text via PolyU eLinks 
Page views
113
Last Week
2
2
Last month
Citations as of Jun 4, 2023
Downloads
147
Citations as of Jun 4, 2023
SCOPUSTM
Citations
618
Last Week
3
3
Last month
Citations as of Jun 1, 2023
WEB OF SCIENCETM
Citations
554
Last Week
2
2
Last month
3
3
Citations as of Jun 1, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.